Grifols SA

1GRF

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    23,800

Stocks News & Analysis

stocks

New ASX share on our best ideas list

This undervalued miner is unappreciated by the market.
stocks

Has the most hated company on the ASX 200 bounced back?

Encouraging results indicate a potential turnaround story.
stocks

Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown

We think Amazon stock looks attractive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,922.004.900.05%
CAC 407,632.0185.851.14%
DAX 4023,757.69331.721.42%
Dow JONES (US)44,144.62556.041.28%
FTSE 1009,128.3059.720.66%
HKSE24,733.45225.640.92%
NASDAQ21,007.35357.211.73%
Nikkei 22540,290.70508.90-1.25%
NZX 50 Index12,684.0445.36-0.36%
S&P 5006,320.9382.921.33%
S&P/ASX 2008,663.701.700.02%
SSE Composite Index3,583.3123.360.66%

Market Movers